The novel dual GLP-1 and GIP receptor agonist tirzepatide was approved in 2023 by the FDA for the treatment of obesity, as around a 15% weight loss was observed in the tirzepatide treated patients [45]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.